Home

Browse

Summary

Statistics

Number of samples

Name	Count
PDX	8
Tumour Sample	41
Patient	3

Host Type

Host type	Count
Testosterone supplemented	5
Castrate	3

Graft Site

Graft site	Count
Subcutaneous	8

Treatment prior to specimen collection

Treatment type	Count
ADT	21
Docetaxel	18
None	13
Cabazitaxel	12
Enzalutamide	12
Abiraterone	10
Zoladex	5
Radiotherapy	5
Carboplatin plus etoposide	5
Niraparib	4
PRRT LuTate and Y-Tate	2
Octreotide	2
Ketoconazole	1
Prednisolone	1
Zoledronate	1
Lutetium psma	1
Pembrolizumab	1
Navelbine	1
Zoladex and cosudex	1

Sample site of clinical sample

Treatment type	Count
Prostate	13
Brain	7
Liver	6
Lymph node	3
Spine	2
Lung	2
Dura	1
Suprapubic Mass	1
Right Lung Sub Pleural Tumour	1
Small Bowel Serosa	1
Tumour Under Diaphragm	1
Peritoneal Nodule Near Colon	1
Tumour Adjacent To Pancreas	1
Left Ilium	1

Sample source

Pathology Tumour Diagnosis

Latest News

Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology. Mol Oncol, 2025 [Read Here]

p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2025 [Read Here]

Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants. European Urology Focus, 2025 [Read Here]

Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer. The Journal of Pathology, 2024 [Read Here]

Low-dose carboplatin modifies the tumour microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nature Communications, 2023 [Read Here]

The future of patient-derived xenografts in prostate cancer research. Nature Reviews Urology, 2023 [Read Here]

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021 [Read Here]

Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. Journal of Pathology, 2021 [Read Here]

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018 [Read Here]